Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia

Himalee S Sabnis; Caroline Keenum; Rebecca W Lewis; Briana Patterson; John Bergsagel; Karen E Effinger; Emily Silverman; Ann C Mertens; Sharon M Castellino

doi:10.1111/bjh.15633

Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia

Br J Haematol. 2019 May;185(4):795-799. doi: 10.1111/bjh.15633. Epub 2018 Nov 8.

Authors

Himalee S Sabnis^{1

2}, Caroline Keenum¹, Rebecca W Lewis², Briana Patterson^{1

2

3}, John Bergsagel^{1

2}, Karen E Effinger^{1

2}, Emily Silverman¹, Ann C Mertens^{1

2}, Sharon M Castellino^{1

2}

Affiliations

¹ Department of Pediatrics, Division of Haematology/Oncology/Bone Marrow Transplantation, Emory University, Atlanta, GA, USA.
² Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
³ Department of Pediatrics, Division of Endocrinology, Emory University, Atlanta, GA, USA.

PMID: 30407613
DOI: 10.1111/bjh.15633

No abstract available

Keywords: Philadelphia chromosome-positive acute lymphoblastic leukaemia; body height; chronic myeloid leukaemia; growth; protein kinase inhibitors.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antineoplastic Agents / adverse effects*
Child
Child, Preschool
Female
Growth Disorders / chemically induced*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Protein Kinase Inhibitors / adverse effects*
Retrospective Studies
Young Adult

Substances

Antineoplastic Agents
Protein Kinase Inhibitors